Latest Biotechnology, Pharmaceutical and Healthcare News - Page: 3
Showing News Articles 51–75 of 567
A Key Exchange On Sarepta Therapeutics’ Promising Muscular Dystrophy Drug
has been one of the most exciting — and, from a stock perspective, best-performing — biotechnology companies this year. One big question: would the limited data Sarepta has so far collected from a very small clinical trial of its drug ete...
The Most Productive Drug Companies Of The Past 10 Years
Over the past 10 years, 278 new drugs have been approved by the Food and Drug Administration, according to data from the InnoThink Center for Research in Biomedical Innovation. One hundred-and-seventy-five of them, or 63% of those approvals, came f...
What Does This $14 Billion Deal Mean For The Future Of DNA Sequencing?
In a deal that could have a big impact on the future of DNA sequencing technology, lab equipment Thermo Fisher Scientific is buying rival Life Technologies for $13.6 billion in cash and the assumption of $2.2 billion in debt. The deal values Life sha...
Drug That Helps Multiple Sclerosis Patients Walk May Also Aid Stroke Victims
Ampyra, a pill approved to help patients with multiple sclerosis walk, has put Acorda Therapeutics in the small club of profitable biotechnology companies. The drug generated $266 million in annual sales last year, helping Acorda generate a net profi...
The Best- And Worst-Performing Biotech Stocks, April 5 To April 12
These are the best and worst-performing medical and biotech stocks from April 5 to April 12, 2013. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had mark...
Myriad Genetics CEO Claims He Owns Your Genes
The CEO of Myriad Genetics wrote a letter to the Washington Post claiming that his company's patents on the breast cancer genes, BRCA1 and BRCA2, were the source of innovation and have benefitted the public. A closer look reveals his gross distortio...
Florida’s Innovative, Consumer-Driven Replacement for Obamacare’s Medicaid Expansion
When Florida was faced with the choice of whether or not to implement Obamacare’s enlargement of Medicaid, Republican governor Rick Scott said yes, but the GOP-controlled legislature said no. That, however, isn’t the end of the story. Yesterday,...
Obama’s 2014 Budget Would Cut or Freeze Many Senior Services
You’ve probably seen the headlines from President Obama’s 2014 budget: He’d slow the growth of Social benefits by changing the way payments are increased for inflation, trim Medicare by cutting payments to providers and making high-income r...
High-Risk Pools and Reinsurance: Potential Shock Waves to Insurers
Due to poorer health, higher cost services and pent up demand for health care, there are numerous concerns about high-risk and expensive individuals. These are people who were previously uninsured or enrolled in high-risk plans that will soon be cove...
Three Questions for Medicare Chief Marilyn Tavenner at her Nomination Hearing
This morning in something novel is underway. A Medicare administrator is having a confirmation hearing for the first time since 2002. Since 2006 the important job has been vacant or filled with recess appointments. Marilyn Tavenner is by all accounts...
Untold Story of Small Biz Delay under ACA, Just Déjà Vu from Massachusetts
The revelation that the Obama Administration will delay the roll out of the “choice option” for small business until 2015 came as a huge surprise to many, including Joe Klein at Time, however anyone familiar with the Massachusetts experiment will...
Dr. Oz Is Worried About Your Teeth. Should You Worry Too?
Dr. Oz aired a show claiming that the mercury in silver tooth fillings can cause all sorts of harm to one's health. Is this true? No. The claims that mercury in tooth fillings cause harm have been circulating for decades and have been thoroughly s...
How Americans Game the $200 Billion-a-Year ‘Disability-Industrial Complex’
If you’re a regular reader of this blog, you know that America’s health-care entitlements—Medicare, Medicaid, and Obamacare—are the biggest drivers of our exploding federal debt. What you may not know is that there is a fourth program, that p...
Roger Ebert Became A Voice For All Those Who Face Cancer Bravely
Roger Ebert has died. He was of course an ever-present fixture for years. He was always on TV, with Gene Siskel, and I read his columns occasionally. But he was not close to my favorite movie critic, nor did he even come close to being someone I want...
Should Arkansas Take the Obamacare Medicaid Deal? Probably Not
Arkansas has attracted national attention over the possibility that the Obama administration might agree to allow Arkansas to implement Obamacare’s Medicaid expansion by enrolling these newly Medicaid-eligible patients on the ACA exchanges. This ha...
California Will Shift 456,000 Low Income Seniors Into Managed Care
has taken the idea of managed care for low-income seniors and people with disabilities to a whole new level. Under an agreement with the Obama Administration announced last week, the state will begin shifting both medical care and long-term supports...
Analyst: Higher Rate Of Genital Fungal Infections Could Curb Sales Of New J&J Drug
On Friday, the Food and Drug Administration approved Johnson & Johnson’s new diabetes pill Invokana, the first in a new class of medicines called SGLT-2 inhibitors. In a note to investors this morning, analyst Lawrence Biegelson of Wells Fa...
The Arkansas-Obamacare Medicaid Deal: Far Less Than It First Appeared
When Arkansas Gov. Mike Beebe (D.) first announced that he had reached a deal with the Obama administration to use the Affordable Care Act’s private insurance exchanges to expand coverage to poor Arkansans, it seemed like an important, and potentia...
Whither Contract Research Organizations: A Glass Half Full?
As drugmakers look to emerge from the patent cliff, R&D spending growth is expected to extremely modest, but more outsourced work should boost contract research organizations.
Biogen Prices New MS Pill At $55K, Prepares For Marketing Battle
Biogen Idec will price it’s new multiple sclerosis pill, Tecfidera, at a wholesale acquisition cost of $54,900 per patient per year. The medicine will distributed, stocked, and available to patients “on or around” this coming Monda...
Yes, Health Care is a Right — An Individual Right
Many moons ago, I served a term as chairman of the Conservative Party of the Yale Political Union, a parliamentary debating society. On March 26, the Union invited me back to keynote a debate on the topic, “Resolved, That Health Care is a Right.”...
Policy Experts Agree: The U.S. System for Financing Long-Term Care is Crumbling
America’s system for financing long-term care is failing, and the window for creating a payment system that works is rapidly closing. That was the conclusion of a morning-long expert session sponsored last week by the SCAN Foundation. While the par...
Merck & Its HPV Vaccine: Sales & Skepticism Are Both Up
Sales of Merck's Gardasil vaccine are climbing even as more parents remain leerly of HPV vaccination, a new survey finds.
A Biotech Billionaire’s Latest Drug Bet Implodes
Biotech investor R.J. Kirk became a billionaire thanks to big bets on two neuroscience drugs: Vyvanse, for attention deficit hyperactivity disorder, and Viibryd, for depression. In both cases he sold the company that developed the medicine to a large...
Blue-State ACA Blues: Connecticut’s ‘Benchmark Plan’ Already Unaffordable
Trudy Lieberman of the Columbia Journalism Review uncovered a problem in the Nutmeg State that highlights an issue that might become more prevalent in states as premiums go up with the additional market regulations required under the ACA. She asks th...
